Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 18,362	$ 36,632
Short-term investments – available for sale	117,302	118,853
Prepaid clinical trial and preclinical study costs	9,878	8,144
Prepaid expenses and other current assets	3,926	3,411
Total current assets	149,468	167,040
Right-of-use assets	1,346	1,418
Deferred financing costs	48	38
Deposits	33	33
Total assets	150,895	168,529
Current liabilities:
Accounts payable	3,799	8,529
Other accrued liabilities	11,541	13,114
Lease liability, current	309	304
Total current liabilities	15,649	21,947
Lease liability, net of current portion	1,181	1,260
Total long-term liabilities	1,181	1,260
Total liabilities	16,830	23,207
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at March 31, 2023 and December 31, 2022; no shares issued and outstanding at March 31, 2023 and December 31, 2022
Common stock, $0.00001 par value: 300,000,000 shares authorized at March 31, 2023 and December 31, 2022; 79,319,081 shares issued and outstanding at March 31, 2023 and 78,257,258 shares issued and outstanding at December 31, 2022	1	1
Treasury stock at cost, 2,193,251 shares at March 31, 2023 and December 31, 2022	(6,795)	(6,795)
Additional paid-in capital	453,057	445,267
Accumulated deficit	(311,580)	(292,049)
Accumulated other comprehensive loss	(618)	(1,102)
Total stockholders’ equity	134,065	145,322
Total liabilities and stockholders’ equity	$ 150,895	$ 168,529